Comments on: Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Comments on: Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis https://thegbm.com/zealand-pharma-announces-boehringer-ingelheims-survodutide-phase-iii-trial-in-people-living-with-obesity-showed-targeted-34-visceral-and-63-liver-fat-reduction-while-minimizing-lean-mass-loss-in-p/ Business news, opinion, reviews, interviews Sun, 07 Jun 2026 18:30:00 +0000 hourly 1 https://wordpress.org/?v=7.0